Zobrazeno 1 - 10
of 364
pro vyhledávání: ''
Autor:
Richard J. Chen, Robert J. Soiffer, Liying Zhang, Anna M. Tanasijevic, Jane A. Driver, Lee Mozessohn, Gregory A. Abel, Andrew Keezer, Jorge J. Castillo, Rena Buckstein, Oreofe O. Odejide
Publikováno v:
Leukemialymphoma. 62(12)
Background: Frailty is associated with poor tolerance to chemotherapy and mortality. While recent evidence suggests measures of frailty such as gait speed predict survival in older patients with hematologic malignancies such as lymphoma (Liu, Blood,
Autor:
Eric Q. Wu, Gaetano Bonifacio, Annie Guerin, Xiting Cao, George J Joseph, Dominick Latremouille-Viau, Eytan M. Stein, Sherry Shi
Publikováno v:
Leukemialymphoma. 62(6)
Background: Hypomethylating agents (HMA), azacitidine (AZA) and decitabine (DEC), are the current standard of care in patients with intermediate-2 and high risk myelodysplastic syndromes (MDS) by IPSS prognostic category (higher-risk MDS) based on cl
Autor:
Amporn Atsawarungruangkit, Christopher McCoy, Nitipong Permpalung, Howard S. Gold, Mary T. LaSalvia, Michael T. Wong, Carolyn D. Alonso, James D. Levine, Monica V Mahoney
Publikováno v:
Leukemialymphoma. 60(1)
Palivizumab has been used to treat respiratory syncytial virus (RSV)-infected hematologic malignancy patients at our institution based on limited published data. We conducted this retrospective study to evaluate clinical outcomes and mortality rates
Autor:
Clare Sun, Sreenivasulu Gunti, Sarah E. M. Herman, Gilberto N. Carmona, Ying Xiong, Raju V.S.R.K. Gottumukkala, Adrian Wiestner, Abner Louis Notkins
Publikováno v:
Leukemialymphoma. 60(1)
Polyreactive antibodies are a major part of natural antibody repertoire and can react with different types of antigens both from the host (e.g. proteins, carbohydrates, lipids, DNA) as well as from...
Autor:
Michihide Tokuhira, Tomoe Anan-Nemoto, Shuji Momose, Jun-ichi Tamaru, Koichi Amano, Shinichiro Okamoto, Shuntaro Saito, Takayuki Shimizu, Katsuya Suzuki, Ayumi Okuyama, Morihiro Higashi, Tsutomu Takeuchi, Masahiro Kizaki, Takehiko Mori
Publikováno v:
Leukemialymphoma. 59(5)
Although recent accumulative data reveal the clinicopathogenesis of regression in methotrexate-induced lymphoproliferative disorders (MTX-LPDs), the precise understanding including this category remains controversial. In this study, we analyzed 62 pa
Autor:
Katja Marin, Päivi Auvinen, Peeter Karihtala, Taina Turpeenniemi-Hujanen, Ylermi Soini, Outi Kuittinen, Hamid Bur, Kirsi-Maria Haapasaari
Publikováno v:
Leukemialymphoma. 59(3)
Sirtuins (SIRTs) are a family of histone deacetylases, which widely regulate cellular metabolism and are also involved in DNA repair. Rap1-interacting factor 1 (Rif1) and O⁶-alkylguanine DNA alkyltransferase (MGMT) are DNA-repair enzymes, which may
Autor:
Katrina Fischer, Sudipto Mukherjee, Ronald Sobecks, Michaela Liedtke, Mikkael A. Sekeres, Anjali S. Advani, Hetty E. Carraway, Ryan D. Cassaday, Caner Saygin, Bhumika J. Patel, Tamara J. Dunn, Betty K. Hamilton, Matt Kalaycio, Nikolaos Papadantonakis, Aaron T. Gerds
Publikováno v:
Leukemialymphoma. 59(2)
Outcomes of relapsed adult acute lymphoblastic leukemia (ALL) have improved over time with the introduction of new therapies as well as better supportive care. However, there is still a need for easy-to-use and accurate prognostic tools for patients
Autor:
Helio Moraes-Souza, Bruna Maria Bereta de Souza, Marcos Vinicius da Silva, Fernanda Bernadelli De Vito, Leonardo Rodrigues de Oliveira, Virmondes Rodrigues-Júnior, Marianna Licati Calado
Publikováno v:
Leukemialymphoma. 59(1)
This study quantified the perforin and granzyme B in patients with non-Hodgkin lymphoma (NHL) at the time of diagnosis. Protein quantification was performed by flow cytometry. NHL patients had a higher number of cytotoxic T lymphocytes (CTLs) express
Autor:
Juan Li, Hui Li, Haihe Wang, Shulan Yang, Hehua Wang, Bin Liu, Fengqi Liu, Mingming Zhang, Limei Xu, Wen Guan, Xiuzhen Tong
Publikováno v:
Leukemialymphoma. 59(4)
Phosphatase PRL-3 expression is positively associated to acute myeloid leukemia (AML) progression and drug resistance. SH3-domain-binding glutamic acid-rich protein-like protein (SH3BGRL), a downstream effector of PRL-3, plays a tumor suppressive rol
Publikováno v:
Leukemialymphoma. 58(12)
Multiple myeloma (MM) is a hematological cancer with underlying causes associated with increased oxidative stress. Through signaling of their receptor RAGE, advanced glycation endproducts (AGEs) are known to increase oxidative stress associated with